Bryan Humbarger Named Chief Commercial Officer at HeartBeam

HeartBeam Inc. has appointed Bryan Humbarger as chief commercial officer. He is tasked with leading commercial strategy and administering the company’s key growth initiatives, including the limited launch of the recently cleared HeartBeam System for arrhythmia assessment, heart attack detection indication, and 12-lead ECG extended wear patch monitor.

Humbarger will lead outreach to the cardiology community, focusing on developing partnerships with channel partners and cardiology practices interested in adopting HeartBeam’s technology. This will enable the company to efficiently validate the HeartBeam System’s real-world performance and establish reference sites.

“Bryan is an exceptional commercial leader with the experience and strategic mindset required to bring category-defining technologies to market,” HeartBeam CEO Robert Eno said. “His understanding of the market will strengthen our ability to execute our limited launch with precision and his track record with partnerships will help to accelerate our progress across the high-impact initiatives that will drive HeartBeam’s growth in the years ahead.”

Humbarger has more than 25 years of commercial leadership experience spanning large medical device organizations and high-growth medtech companies. Most recently, he was chief commercial officer at the venture-backed surgical guidance company Proprio, where he led the go-to-market strategy and market development while establishing the company’s sales and clinical support infrastructure. His background also includes senior commercial leadership roles at Heartflow, AliveCor, and Eko Health.

“I am honored to join HeartBeam as the team is bringing disruptive technology to address a real and growing need in cardiac care—delivering advanced, clinical-grade insights to patients wherever they are,” Humbarger stated. “HeartBeam’s platform technology has the potential to transform cardiac care for millions of patients, and I am excited to establish a commercial foundation that scales for long-term success.”

HeartBeam Inc. is a medical technology company transforming the detection and monitoring of critical cardiac conditions. The company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care—all outside of a medical facility—thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received U.S. Food and Drug Administration (FDA) clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 2025.¹ The company holds more than 20 issued patents related to technology enablement. For additional information, visit HeartBeam.com.

Reference
¹ Cleared Indications for Use: Refer to the Company’s Cleared Indications for Use at https://www.heartbeam.com/indications for details on the intended use of its technology.